Dysbiosis: Clinical Trials

13 trials for Dysbiosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 terminated, 2 active not recruiting, 2 completed. 13 Phase 2, 4 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Recruiting 4, Terminated 3, Active not recruiting 2, Completed 2, Unknown 1, Withdrawn 1
Phase 14Terminated 2, Active not recruiting 1, Withdrawn 1
Phase 32Terminated 1, Unknown 1

Follow Dysbiosis: new trials by email Literature Review of Dysbiosis trials Research Report on Dysbiosis

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome
Biocidin REMOVE, Placebo - Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Phase 2RecruitingJohns Hopkins University402026-10-262026-11-16
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
EXL01 - Hepatocellular Carcinoma
Phase 2RecruitingCenter Eugene Marquis342025-03-122025-08-05
Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study
FMT capsules, Placebo capsules - HIV-1-infection
Phase 2CompletedJean-Pierre Routy202024-07-312025-09-03
INVESTIGATION of the EFFICACY and SAFETY of the DRUG "AS-PROBIONORM"
"AS-Probionorm" - Intestinal Infections, Dysbacteriosis
Phase 2CompletedIndustrial Microbiology LLP2102024-07-222025-03-20
Microbiome Alterations With Xylitol (MAX) in Pregnancy
Xylitol gum, Sorbitol gum - Dysbiosis, Inflammation Gum
Phase 1 / Phase 2Active not recruitingBaylor College of Medicine802024-06-132026-03-10
Fecal Microbiota Transplantation in Axial Spondyloarthritis
FMT, Placebo - Axial Spondyloarthritis, Ankylosing Spondylitis
Phase 2RecruitingUniversity Hospital of North Norway992024-06-012026-08-14
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
Probiotic, Placebo - Microtia, Dysbiosis
Phase 2RecruitingVanderbilt University Medical Center2502023-09-182026-08-27
Oral Iron Supplementation for Patients With Chronic Kidney Disease
Ferrous sulfate 3 days week, Ferrous sulfate daily, Ferrous sulfate higher concentration - Chronic Renal Disease, Iron-Deficiency Anemia
Phase 2Active not recruitingUniversidade Federal Fluminense62022-08-012025-04-03
Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children
Pancreatic Enzyme, Ursodeoxycholic acid, Pancreatic Enzyme placebo - SEPSIS, MALNUTRITION, CHILD
Phase 2 / Phase 3UnknownUniversity of Oxford4002021-07-012023-02-24
Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis
Rosuvastatin 10mg - Ulcerative Colitis
Phase 2 / Phase 3TerminatedUniversitaire Ziekenhuizen KU Leuven1772020-10-222025-11-25
Fecal Microbiota Transplant for Primary CDI
Fecal microbiota transplant G3 capsules, Oral Vancomycin alone - Clostridium Difficile Infection
Phase 1 / Phase 2TerminatedBoston Medical Center52019-08-232021-12-15
Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)
Fecal Microbiota Transplantation (FMT), Saline - Clostridial Infection, Dysbiosis
Phase 1 / Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)102019-01-112022-05-02
SHIFT: Studying HIV Immunology After Fecal Transplant
Fecal Inoculum Capsule, Placebo (for Fecal Inoculum Capsule), Antibiotic - HIV/AIDS, Dysbiosis
Phase 1 / Phase 2WithdrawnMassachusetts General Hospital2018-06-012018-11-15

Narrower conditions

Inflammation (3)  ·  Clostridium Infections (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Alcohol Drinking (1)  ·  Anemia, Iron-Deficiency (1)  ·  Arthritis (1)  ·  Axial Spondyloarthritis (1)  ·  Carcinoma, Hepatocellular (1)  ·  Cardiovascular Diseases (1)  ·  Child Nutrition Disorders (1)  ·  Colitis, Ulcerative (1)  ·  Congenital Microtia (1)  ·  Gingivitis (1)  ·  HIV Infections (1)

Broader conditions

Pathologic Processes (13)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Infections (7)  ·  Digestive System Diseases (3)  ·  Urogenital Diseases (3)  ·  Bacterial Infections (2)  ·  Bacterial Infections and Mycoses (2)  ·  Blood-Borne Infections (2)  ·  Colonic Diseases (2)  ·  Communicable Diseases (2)  ·  Gastrointestinal Diseases (2)  ·  Genital Diseases (2)  ·  Gram-Positive Bacterial Infections (2)  ·  Immune System Diseases (2)  ·  Immunologic Deficiency Syndromes (2)

Interventions

Fecal Microbiota Transplantation (2)  ·  Anti-Bacterial Agents (1)  ·  Pancrelipase (1)  ·  Probiotics (1)  ·  Rosuvastatin Calcium (1)  ·  Sodium Chloride (1)  ·  Ursodeoxycholic Acid (1)  ·  Vancomycin (1)  ·  ferrous sulfate (1)

Sponsors

Baylor College of Medicine (1)  ·  Boston Medical Center (1)  ·  Center Eugene Marquis (1)  ·  Industrial Microbiology LLP (1)  ·  Jean-Pierre Routy (1)  ·  Johns Hopkins University (1)  ·  Massachusetts General Hospital (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Universidade Federal Fluminense (1)  ·  Universitaire Ziekenhuizen KU Leuven (1)  ·  University Hospital of North Norway (1)  ·  University of Oxford (1)  ·  Vanderbilt University Medical Center (1)

Countries

United States (4)  ·  Malawi (2)  ·  Bangladesh (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  France (1)  ·  Kazakhstan (1)  ·  Kenya (1)  ·  Norway (1)  ·  Uganda (1)

Top investigators

Benjamin Shayo, MD (1)  ·  Carolina Berini, Dr. (1)  ·  Douglas Kwon, MD, PhD (1)  ·  Gerry Mullin, MD (1)  ·  Ilyas Kulmagambetov, Doctor of Med. Sc. (1)  ·  James A Berkley, MD (1)  ·  Jeroen Raes, PhD (1)  ·  Severine Vermeire, MD & PhD (1)  ·  Tamar Barlam, MD MSC (1)

Results publications

PMID 22265264, PMID 24891990, PMID 28390459, PMID 28605006, PMID 29100842, PMID 29615661, PMID 30480772, PMID 31270648, PMID 32173258, PMID 32385871, PMID 32433595, PMID 32600259, PMID 32633595, PMID 34677696, PMID 35562576, PMID 35601423, PMID 35998741, PMID 36239787, PMID 36733569, PMID 41390455, PMID 42643234

NIH funding

D43TW012274 (1)